The cellular mechanisms of dry eye: From pathogenesis to treatment

Journal of Cellular Physiology

Volumn 228, Issue 12, 2013, Pages 2253-2256

  Mantelli, Flavio ^a   Massaro Giordano, Mina ^b   Macchi, Ilaria ^c   Lambiase, Alessandro ^c   Bonini, Stefano ^c  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCITONIN; CYCLOSPORIN A; EYE DROPS; GALECTIN 3; LUBRICATING AGENT; MUCIN; NEUROTROPHIN RECEPTOR P75; PROTEIN TYROSINE KINASE A; SUBSTANCE P;

CATARACT; CELL DAMAGE; CHRONIC INFLAMMATION; CONJUNCTIVITIS; CORTICOSTEROID THERAPY; DRY EYE; EPITHELIUM CELL; GLAUCOMA; HUMAN; LACRIMATION; LONG TERM CARE; NONHUMAN; OCULAR SURFACE DISEASE; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; TEAR FILM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRY EYE SYNDROMES; EPITHELIUM; GOBLET CELLS; HUMANS; MUCINS; TEARS;

EID: 84883015045     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24398     Document Type: Review

References (40)

1. Andrianifahanana M, Moniaux N, Batra SK. 2006. Regulation of mucin expression: Mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 1765:189-222.
2. Argüeso P, Guzman-Aranguez A, Mantelli F, Cao Z, Ricciuto J, Panjwani N. 2009. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem 284:23037-23045.
3. Beuerman RW, Stern ME. 2005. Neurogenic inflammation: A first line of defense for the ocular surface. Ocul Surf 3:S203-S206.
4. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V, Gipson IK. 2007. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 48:4509-4518.
5. Chang EJ, Im YS, Kay EP, Kim JY, Lee JE, Lee HK. 2008. The role of nerve growth factor in hyperosmolar stress induced apoptosis. J Cell Physiol 216:69-77.
6. Chung CW, Tigges M, Stone RA. 1996. Peptidergic innervation of the primate meibomian gland. Invest Ophthalmol Vis Sci 37:238-245.
7. Coassin M, Lambiase A, Costa N, De Gregorio A, Sgrulletta R, Sacchetti M, Aloe L, Bonini S. 2005. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol 243:151-155.
8. Dartt DA, Kessler TL, Chung E-H, Zieske JD. 1996. Vasoactive intestinal peptide stimulated glycoconjugate secretion from conjunctival goblet cells. Exp Eye Res 63:27-34.
9. Dry Eye Workshop. 2007a. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf 5:75-92.
10. Dry Eye Workshop. 2007b. Methodologies to diagnose and monitor dry eye disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop. Ocul Surf 5:108-152.
11. Dry Eye Workshop. 2007c. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf 5:163-178.
12. Kovács I, Ludány A, Koszegi T, Fehér J, Kovács B, Szolcsányi J, Pintér E. 2005. Substance P released from sensory nerve endings influences tear secretion and goblet cell function in the rat. Neuropeptides 39:395-402.
13. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. 2008. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398-410.
14. Kunert KS, Tisdale AS, Gipson IK. 2002. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 120:330-337.
15. Lambiase A, Bonini S, Micera A, Rama P, Bonini S, Aloe L. 1998a. Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci 39:1272-1275.
16. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. 1998b. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 338:1174-1180.
17. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V, Manni GL, Bucci MG, Bonini S, Levi-Montalcini R. 2009a. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci USA 106:13469-13474.
18. Lambiase A, Micera A, Pellegrini G, Merlo D, Rama P, De Luca M, Bonini S, Bonini S. 2009b. In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci 50:4622-4630.
19. Lambiase A, Mantelli F, Sacchetti M, Rossi S, Aloe L, Bonini S. 2011. Clinical applications of NGF in ocular diseases. Arch Ital Biol 149:283-292.
20. Lambiase A, Aloe L, Mantelli F, Sacchetti M, Perrella E, Bianchi P, Rocco ML, Bonini S. 2012. Capsaicin-induced corneal sensory denervation and healing impairment are reversed by NGF treatment. Invest Ophthalmol Vis Sci 53:8280-8287.
21. Lee HK, Lee KS, Kim HC, Lee SH, Kim EK. 2005. Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am J Ophthal 139:965-971.
22. Lemp MA. 2008. Management of dry eye disease. Am J Manag Care 14:S88-S101.
23. Mantelli F, Argüeso P. 2008. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol 8:477-483.
24. Mantelli F, Tiberi E, Micera A, Lambiase A, Visintini F, Bonini S. 2007. MUC5AC overexpression in tear film of neonates. Graefes Arch Clin Exp Ophthalmol 245:1377-1381.
25. Mantelli F, Schaffer L, Dana R, Head SR, Argüeso P. 2009. Glycogene expression in conjunctiva of patients with dry eye: Downregulation of Notch signaling. Invest Ophthalmol Vis Sci 50:2666-2672.
26. Mantelli F, Micera A, Sacchetti M, Bonini S. 2010. Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol 10:498-504.
27. Matsuda S, Koyasu S. 2000. Mechanisms of action of cyclosporine. Immunopharmacology 47:119-125.
28. McKenzie RW, Jumblatt JE, Jumblatt MM. 2000. Quantification of MUC2 and MUC5AC transcripts in human conjunctiva. Invest Ophthalmol Vis Sci 41:703-708.
29. Micera A, Lambiase A, Bonini S. 2008. The role of neuromediators in ocular allergy. Curr Opin Allergy Clin Immunol 8:466-471.
30. Moore JE, Vasey GT, Dartt DA, McGilligan VE, Atkinson SD, Grills C, Lamey PJ, Leccisotti A, Frazer DG, Moore TC. 2011. Effect of tear hyperosmolarity and signs of clinical ocular surface pathology upon conjunctival goblet cell function in the human ocular surface. Invest Ophthalmol Vis Sci 52:6174-6180.
31. Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner MA. 1993. Substance P, calcitonin generelated peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J Allergy Clin Immunol 92:95-104.
32. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. 2008. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 27:64-69.
33. Springer J, Geppetti P, Fischer A, Groneberg DA. 2003. Calcitonin gene-related peptide as inflammatory mediator. Pulm Pharmacol Ther 16:121-130.
34. Stevenson W, Chauhan SK, Dana R. 2012. Dry eye disease: An immune-mediated ocular surface disorder. Arch Ophthalmol 130:90-100.
35. Sumiyoshi M, Ricciuto J, Tisdale A, Gipson IK, Mantelli F, Argüeso P. 2008. Antiadhesive character of mucin O-glycans at the apical surface of corneal epithelial cells. Invest Ophthalmol Vis Sci 49:197-203.
36. Tatebayashi K, Tanaka K, Yang HY, Yamamoto K, Matsushita Y, Tomida T, Imai M, Saito H. 2007. Transmembrane mucins Hkr1 and Msb2 are putative osmosensors in the SHO1 branch of yeast HOG pathway. EMBO J 26:3521-3533.
37. Tuisku IS, Konttinen YT, Konttinen LM, Tervo TM. 2008. Alterations in corneal sensitivity and nerve morphology in patients with primary Sjögren's syndrome. Exp Eye Res 86:879-885.
38. Uchino Y, Kawakita T, Miyazawa M, Ishii T, Onouchi H, Yasuda K, Ogawa Y, Shimmura S, Ishii N, Tsubota K. 2012. Oxidative stress induced inflammation initiates functional decline of tear production. PLoS ONE 7:e45805.
39. Utine CA, Stern M, Akpek EK. 2010. Clinical review: Topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 18:352-361.
40. Yu DF, Chen Y, Han JM, Zhang H, Chen XP, Zou WJ, Liang LY, Xu CC, Liu ZG. 2008. MUC19 expression in human ocular surface and lacrimal gland and its alteration in Sjogren syndrome patients. Exp Eye Res 86:403-411.